Neurocrine Biosciences Inc
NASDAQ:NBIX

Watchlist Manager
Neurocrine Biosciences Inc Logo
Neurocrine Biosciences Inc
NASDAQ:NBIX
Watchlist
Price: 154.99 USD -0.33% Market Closed
Market Cap: 15.5B USD

Neurocrine Biosciences Inc
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Neurocrine Biosciences Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Neurocrine Biosciences Inc
NASDAQ:NBIX
Stock-Based Compensation
$225.7m
CAGR 3-Years
11%
CAGR 5-Years
18%
CAGR 10-Years
25%
Abbvie Inc
NYSE:ABBV
Stock-Based Compensation
$962m
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Stock-Based Compensation
$886m
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Stock-Based Compensation
$503m
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Stock-Based Compensation
$696.1m
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
12%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Stock-Based Compensation
$1B
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
10%
No Stocks Found

Neurocrine Biosciences Inc
Glance View

Neurocrine Biosciences Inc. is a biopharmaceutical company that has carved out a notable niche in the neurosciences landscape. Founded in 1992, this San Diego-based firm has dedicated itself to developing treatments for neurological and endocrine-related disorders. With a strong focus on conditions such as Parkinson's disease, tardive dyskinesia, and epilepsy, Neurocrine leverages its expertise in neuroscience to bring innovative therapies to those who need them most. The company’s flagship product, Ingrezza, primarily used to treat tardive dyskinesia, reflects their commitment to addressing complex, unmet medical needs. Successfully obtaining FDA approval not only boosted patient outcomes but also established Neurocrine as a leader in a specialized segment of the pharmaceutical industry. Neurocrine’s financial model thrives on the commercialization of its proprietary medications. By partnering strategically with other pharmaceutical giants, such as AbbVie, they can broaden their market reach and accelerate development of new treatments. The company generates revenue predominantly through product sales, royalties, and milestone payments associated with its collaborations. Their pipeline remains robust, focusing on both expanding indications for existing drugs and pioneering new treatments. Each new approval or advancement in clinical trials further solidifies their market position and offers potential for increased financial returns. Thus, Neurocrine Biosciences operates at the intersection of science and business, continuously pushing the boundaries of neurological treatment while maintaining a steady growth trajectory.

NBIX Intrinsic Value
HIDDEN
Show

See Also

What is Neurocrine Biosciences Inc's Stock-Based Compensation?
Stock-Based Compensation
225.7m USD

Based on the financial report for Sep 30, 2025, Neurocrine Biosciences Inc's Stock-Based Compensation amounts to 225.7m USD.

What is Neurocrine Biosciences Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
25%

Over the last year, the Stock-Based Compensation growth was 35%. The average annual Stock-Based Compensation growth rates for Neurocrine Biosciences Inc have been 11% over the past three years , 18% over the past five years , and 25% over the past ten years .

Back to Top